Rivastigmine treatment resulted in significantly lower hepatic TG content and plasma ALT levels in the animals developing MASH, compared to vehicle-control mice, suggesting that drug treatment ameliorated MASH-associated steatosis and liver damage (Fig 4F and 4G). This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.